Point-of-Care COVID-19 Antibody Test
The point-of-care COVID-19 Antibody Test is a solid phase immunochromatographic assay for the rapid, qualitative and differential detection of IgG and IgM antibodies to 2019 Novel Coronavirusi in human whole blood, serum or plasma.
The COVID-19 IgG/IgM Rapid Test is an essential screening test that enables healthcare professionals to make determinations of patients’ status after contracting COVID-19. This test provides only a preliminary test result. Therefore, any reactive specimen with the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) should be confirmed with alternative diagnostic testing method(s) and clinical findings.
CLIA Waived for medical professional use.
- Results in 10 minutes
- Detection window: Symptomatic 5 days, Asymptomatic 7 days
- Easy to administer: A small finger-prick blood sample
- Reliable results at a fraction of the cost and time of PCR or ELISA tests
- Test medium: Whole blood, plasma and serum samples
- 18 month shelf life from manufacture date
What is the difference between IgM and IgG antibodies?
IgM is the first antibody to be produced in response to any antigen (foreign particle) invasion. While IgG is most abundantly found antibody in the human body, IgM is thelargest immunoglobulin among all.
Simply put, IgM will be the first antibody produced by the body if a virus is present in the body. While IgG is the second antibody produced by the body in response to a virus, it will remain longer and is an indicator that the body has produced some level of immunity. There is no final data that suggests the presence of IgG antibodies will protect against future COVID-19 exposure.